Liquid biopsy may predict bladder cancer outcomes, new study hopes

NCT ID NCT07581496

Recruiting now Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated Jun 12, 2026 · Updated 7 times

Summary

This study is looking at whether tiny bits of tumor DNA (ctDNA) found in blood or urine can help doctors better understand and predict the course of a high-risk type of bladder cancer called T1G3. About 35 adults with this cancer will provide samples before, during, and after treatment. The goal is to see if ctDNA can tell which patients need more aggressive therapy and which can avoid it, potentially reducing unnecessary surgeries and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Luzerner Kantonsspital
RECRUITING

Lucerne, Switzerland

Contact Email: •••••@•••••

Contact

Contact Email: •••••@•••••
Universitätsspital Basel
RECRUITING

Basel, Switzerland

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BLADDER CANCER